Dr. Martens (LON:DOCS) Stock Price Down 12.4% – Should You Sell?

Shares of Dr. Martens plc (LON:DOCS) dropped 12.4% during trading on Tuesday . The company traded as low as GBX 65 and last traded at GBX 66.30. Approximately 4,229,807 shares were traded during trading, an increase of 138% from the average daily volume of 1,776,838 shares. The stock had previously closed at GBX 75.65.

Key Stories Impacting Dr. Martens

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Reducing discounting to protect margins — Management plans to scale back promotions and markdowns, which should help gross margins and underpin profitability if sell?through holds. Dr Martens projects flat 2026 revenue as it scales back discounts
• Neutral Sentiment: Balance?sheet and valuation snapshot — DOCS has a market cap ~£638m, a PE around 38.9, quick ratio ~1.13 and current ratio ~2.85; leverage (debt/equity ~127) and a beta ~0.11 suggest limited market sensitivity but meaningful financial leverage to monitor.
• Negative Sentiment: Flat 2026 revenue guidance — Management’s explicit guidance for flat revenue signals a pause in top?line growth and is being read as cautious for demand and near?term momentum. Dr Martens projects flat 2026 revenue as it scales back discounts
• Negative Sentiment: Market reaction and technicals — Shares are trading down today and sit below both the 50?day (GBX 76.53) and 200?day (GBX 83.47) moving averages, indicating recent selling pressure and a weaker short?term trend.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 27th. Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Trading Down 12.4%

The stock has a market cap of £640.83 million, a P/E ratio of 39.00, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The firm’s fifty day simple moving average is GBX 76.53 and its 200-day simple moving average is GBX 83.47.

Dr. Martens (LON:DOCS) last issued its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Equities research analysts expect that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Insider Activity

In other Dr. Martens news, insider Robert Hanson bought 96,000 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was acquired at an average price of GBX 79 per share, with a total value of £75,840. Insiders purchased 97,130 shares of company stock worth $7,673,816 over the last 90 days. 2.79% of the stock is currently owned by insiders.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.